Date:8/8/2011

ks relating to Luminex's foreign operations, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies, or selected assets into our consolidated business operations, including the ability to recognize the benefits of our acquisitions, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2011 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

LUMINEX CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)June 30,December 31,20112010(unaudited)ASSETSCurrent assets:Cash and cash equivalents

$
55,610$
89,487Restricted cash

1,0041,002Short-term investments

29,98328,404Accounts receivable, net

15,68620,936Inventories, net

29,32724,932Deferred income taxes

1,3204,225Prepaids and other

4,0482,732Total current assets

136,978171,718Property and equipment, net

23,66922,084Intangible assets, net

32,24112,944Deferred income taxes

8,4926,363Long-term investments

19,7576,021Goodwill

46,26942,250Other

6,0204,430Total assets

$
273,426$
265,810LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$
4,558$
7,621Accrued liabilities

6,4077,444Deferred revenue

3,6733,866Current portion of long term debt

466849Total current liabilities

15,10419,780Long-term debt

3,1193,351Deferred revenue<
'/>"/>

SOURCE Luminex Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
2. Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011
3. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
4. Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System
5. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
6. Luminex and Life Technologies Sign Agreement for Global Distribution of the Award-Winning MAGPIX® Multiplexing Instrument
7. Luminex Corporation to Present at Jefferies 2011 Global Healthcare Conference
8. Luminex Corporation Reports First Quarter 2011 Results
9. Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011
10. Luminex Corporation Wins Prestigious Medical Design Excellence Award
11. Luminex Corporation to Present at Cowen and Companys 31st Annual Health Care Conference